^
    5d
    A Study of ERAS-601 in People With Chordoma (clinicaltrials.gov)
    P1/2, N=12, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=46 --> 12
    Enrollment closed • Enrollment change
    |
    ERAS-601
    14d
    FLAGSHP-1: A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=90, Active, not recruiting, Erasca, Inc. | N=200 --> 90 | Trial completion date: Feb 2026 --> Jun 2026 | Trial primary completion date: Nov 2025 --> Feb 2026
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • ERAS-601
    3ms
    A Study of ERAS-601 in People With Chordoma (clinicaltrials.gov)
    P1/2, N=46, Recruiting, Memorial Sloan Kettering Cancer Center | N=11 --> 46
    Enrollment change
    |
    ERAS-601
    11ms
    A Study of ERAS-601 in People With Chordoma (clinicaltrials.gov)
    P1/2, N=10, Recruiting, Memorial Sloan Kettering Cancer Center
    New P1/2 trial
    |
    ERAS-601
    1year
    FLAGSHP-1: A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=200, Active, not recruiting, Erasca, Inc. | Trial completion date: Jul 2025 --> Feb 2026 | Trial primary completion date: May 2025 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • ERAS-601
    over1year
    FLAGSHP-1: A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=200, Active, not recruiting, Erasca, Inc. | Trial completion date: May 2024 --> Jul 2025 | Trial primary completion date: May 2024 --> May 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • ERAS-601
    over1year
    HERKULES-1: A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=200, Active, not recruiting, Erasca, Inc. | Phase classification: P1b/2 --> P1/2 | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: May 2024 --> May 2025
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    ERAS-007 • ERAS-601
    over2years
    FLAGSHP-1: A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=200, Active, not recruiting, Erasca, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • ERAS-601
    over2years
    HERKULES-2: A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC (clinicaltrials.gov)
    P1b, N=24, Completed, Erasca, Inc. | Active, not recruiting --> Completed | N=200 --> 24 | Trial completion date: Mar 2024 --> Apr 2023
    Trial completion • Enrollment change • Trial completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • EGFR mutation • KRAS G12C
    |
    Tagrisso (osimertinib) • Lumakras (sotorasib) • ERAS-007 • ERAS-601
    almost3years
    HERKULES-1: A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1b/2, N=200, Active, not recruiting, Erasca, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    ERAS-007 • ERAS-601
    3years
    HERKULES-2: A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC (clinicaltrials.gov)
    P1b, N=200, Active, not recruiting, Erasca, Inc. | Recruiting --> Active, not recruiting | Phase classification: P1b/2 --> P1b
    Enrollment closed • Phase classification • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • EGFR mutation • KRAS G12C
    |
    Tagrisso (osimertinib) • Lumakras (sotorasib) • ERAS-007 • ERAS-601
    almost4years
    HERKULES-4: A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies (clinicaltrials.gov)
    P1b/2, N=0, Withdrawn, Erasca, Inc. | N=120 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    Xospata (gilteritinib) • ERAS-007 • ERAS-601